BRIEF-Cynata Therapeutics Says Cyp-001S FDA Approval Pathway Not Impeded

Reuters
16 May
BRIEF-Cynata <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Says Cyp-001S FDA Approval Pathway Not Impeded

May 16 (Reuters) - Cynata Therapeutics Ltd CYP.AX:

  • CYP-001S FDA APPROVAL PATHWAY NOT IMPEDED

  • CONSIDERS ORPHAN-DRUG EXCLUSIVITY RECENTLY GRANTED BY US FDA WILL NOT IMPEDE APPROVAL OF CYP-001

Further company coverage: CYP.AX

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10